Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive 131I whole body scan?

A. Piccardo, L. Foppiani, S. Morbelli, P. Bianchi, F. Barbera, E. Biscaldi, V. Altrinetti, G. Villavecchia, M. Cabria

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aim. Stage-IV differentiated thyroid cancer (DTC) patients may present elevated serum thyroglobulin (Tg) levels associated with positive [ 131I] whole-body-scan (WBS). Nevertheless some patients in whom WBS does not reveal new sites of disease show increased Tg levels. This finding prompts thorough restaging in order to exclude the presence of metastases unable to concentrate iodine. The aim of our study was to evaluate the impact of [18F]FDG-PET/CT in both the assessment of overall extent of the disease and the therapeutic management in a group of stage-IV DTC patients. Methods. On suspicious of non-iodine concentrating additional metastases, 20 stage-IV DTC patients with increasing Tg levels and stable positive post-therapy WBS were enrolled. Conventional imaging (CI) procedures, including neck ultrasonography, bone-scintigraphy and computed tomography (CT) were performed before [18F]FDG-PET/CT. Results. [18F]FDG-PET/CT was positive in 16 out of 20 patients (80%). In 9 patients (45%) [18F]FDG PET/CT detected a larger number of tumour recurrences/metastatic sites than WBS+CI. [18F]FDG PET/CT findings prompted modification of the management of 11 patients (55%), in whom surgery or external radiotherapy were eventually considered more appropriate than radioactive iodine therapy. These further therapies improved the quality of life in several patients but did not change their survival rate. Conclusions. Our results showed that [ 18F]FDG-PET/CT can detect new radioiodine-negative metastases in advanced DTC patients with unchanged positive WBS and increasing Tg levels. [18F]FDG-PET/CT may constitute a useful tool in the choice of the best therapeutic strategy in such difficult cases.

Original languageEnglish
Pages (from-to)57-65
Number of pages9
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume55
Issue number1
Publication statusPublished - Feb 2011

Fingerprint

Whole Body Imaging
Fluorodeoxyglucose F18
Thyroid Neoplasms
Tomography
Thyroglobulin
Therapeutics
Neoplasm Metastasis
Iodine
Disease Management
Radionuclide Imaging
Ultrasonography
Neck
Radiotherapy
Survival Rate
Quality of Life
Bone and Bones
Recurrence

Keywords

  • F-Fluorodeoxyglucose positron emission tomography
  • Computed tomography
  • Thyroid neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive 131I whole body scan? / Piccardo, A.; Foppiani, L.; Morbelli, S.; Bianchi, P.; Barbera, F.; Biscaldi, E.; Altrinetti, V.; Villavecchia, G.; Cabria, M.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 55, No. 1, 02.2011, p. 57-65.

Research output: Contribution to journalArticle

Piccardo, A, Foppiani, L, Morbelli, S, Bianchi, P, Barbera, F, Biscaldi, E, Altrinetti, V, Villavecchia, G & Cabria, M 2011, 'Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive 131I whole body scan?', Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 55, no. 1, pp. 57-65.
Piccardo, A. ; Foppiani, L. ; Morbelli, S. ; Bianchi, P. ; Barbera, F. ; Biscaldi, E. ; Altrinetti, V. ; Villavecchia, G. ; Cabria, M. / Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive 131I whole body scan?. In: Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2011 ; Vol. 55, No. 1. pp. 57-65.
@article{03b309d0fc554d219a9dc148c494892f,
title = "Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive 131I whole body scan?",
abstract = "Aim. Stage-IV differentiated thyroid cancer (DTC) patients may present elevated serum thyroglobulin (Tg) levels associated with positive [ 131I] whole-body-scan (WBS). Nevertheless some patients in whom WBS does not reveal new sites of disease show increased Tg levels. This finding prompts thorough restaging in order to exclude the presence of metastases unable to concentrate iodine. The aim of our study was to evaluate the impact of [18F]FDG-PET/CT in both the assessment of overall extent of the disease and the therapeutic management in a group of stage-IV DTC patients. Methods. On suspicious of non-iodine concentrating additional metastases, 20 stage-IV DTC patients with increasing Tg levels and stable positive post-therapy WBS were enrolled. Conventional imaging (CI) procedures, including neck ultrasonography, bone-scintigraphy and computed tomography (CT) were performed before [18F]FDG-PET/CT. Results. [18F]FDG-PET/CT was positive in 16 out of 20 patients (80{\%}). In 9 patients (45{\%}) [18F]FDG PET/CT detected a larger number of tumour recurrences/metastatic sites than WBS+CI. [18F]FDG PET/CT findings prompted modification of the management of 11 patients (55{\%}), in whom surgery or external radiotherapy were eventually considered more appropriate than radioactive iodine therapy. These further therapies improved the quality of life in several patients but did not change their survival rate. Conclusions. Our results showed that [ 18F]FDG-PET/CT can detect new radioiodine-negative metastases in advanced DTC patients with unchanged positive WBS and increasing Tg levels. [18F]FDG-PET/CT may constitute a useful tool in the choice of the best therapeutic strategy in such difficult cases.",
keywords = "F-Fluorodeoxyglucose positron emission tomography, Computed tomography, Thyroid neoplasms",
author = "A. Piccardo and L. Foppiani and S. Morbelli and P. Bianchi and F. Barbera and E. Biscaldi and V. Altrinetti and G. Villavecchia and M. Cabria",
year = "2011",
month = "2",
language = "English",
volume = "55",
pages = "57--65",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive 131I whole body scan?

AU - Piccardo, A.

AU - Foppiani, L.

AU - Morbelli, S.

AU - Bianchi, P.

AU - Barbera, F.

AU - Biscaldi, E.

AU - Altrinetti, V.

AU - Villavecchia, G.

AU - Cabria, M.

PY - 2011/2

Y1 - 2011/2

N2 - Aim. Stage-IV differentiated thyroid cancer (DTC) patients may present elevated serum thyroglobulin (Tg) levels associated with positive [ 131I] whole-body-scan (WBS). Nevertheless some patients in whom WBS does not reveal new sites of disease show increased Tg levels. This finding prompts thorough restaging in order to exclude the presence of metastases unable to concentrate iodine. The aim of our study was to evaluate the impact of [18F]FDG-PET/CT in both the assessment of overall extent of the disease and the therapeutic management in a group of stage-IV DTC patients. Methods. On suspicious of non-iodine concentrating additional metastases, 20 stage-IV DTC patients with increasing Tg levels and stable positive post-therapy WBS were enrolled. Conventional imaging (CI) procedures, including neck ultrasonography, bone-scintigraphy and computed tomography (CT) were performed before [18F]FDG-PET/CT. Results. [18F]FDG-PET/CT was positive in 16 out of 20 patients (80%). In 9 patients (45%) [18F]FDG PET/CT detected a larger number of tumour recurrences/metastatic sites than WBS+CI. [18F]FDG PET/CT findings prompted modification of the management of 11 patients (55%), in whom surgery or external radiotherapy were eventually considered more appropriate than radioactive iodine therapy. These further therapies improved the quality of life in several patients but did not change their survival rate. Conclusions. Our results showed that [ 18F]FDG-PET/CT can detect new radioiodine-negative metastases in advanced DTC patients with unchanged positive WBS and increasing Tg levels. [18F]FDG-PET/CT may constitute a useful tool in the choice of the best therapeutic strategy in such difficult cases.

AB - Aim. Stage-IV differentiated thyroid cancer (DTC) patients may present elevated serum thyroglobulin (Tg) levels associated with positive [ 131I] whole-body-scan (WBS). Nevertheless some patients in whom WBS does not reveal new sites of disease show increased Tg levels. This finding prompts thorough restaging in order to exclude the presence of metastases unable to concentrate iodine. The aim of our study was to evaluate the impact of [18F]FDG-PET/CT in both the assessment of overall extent of the disease and the therapeutic management in a group of stage-IV DTC patients. Methods. On suspicious of non-iodine concentrating additional metastases, 20 stage-IV DTC patients with increasing Tg levels and stable positive post-therapy WBS were enrolled. Conventional imaging (CI) procedures, including neck ultrasonography, bone-scintigraphy and computed tomography (CT) were performed before [18F]FDG-PET/CT. Results. [18F]FDG-PET/CT was positive in 16 out of 20 patients (80%). In 9 patients (45%) [18F]FDG PET/CT detected a larger number of tumour recurrences/metastatic sites than WBS+CI. [18F]FDG PET/CT findings prompted modification of the management of 11 patients (55%), in whom surgery or external radiotherapy were eventually considered more appropriate than radioactive iodine therapy. These further therapies improved the quality of life in several patients but did not change their survival rate. Conclusions. Our results showed that [ 18F]FDG-PET/CT can detect new radioiodine-negative metastases in advanced DTC patients with unchanged positive WBS and increasing Tg levels. [18F]FDG-PET/CT may constitute a useful tool in the choice of the best therapeutic strategy in such difficult cases.

KW - F-Fluorodeoxyglucose positron emission tomography

KW - Computed tomography

KW - Thyroid neoplasms

UR - http://www.scopus.com/inward/record.url?scp=79957512836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957512836&partnerID=8YFLogxK

M3 - Article

C2 - 21285923

AN - SCOPUS:79957512836

VL - 55

SP - 57

EP - 65

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 1

ER -